Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T16:34:02.422Z.
Calculation as of: 2026-10-06T16:34:02.422Z.
Quote observation: 2026-10-06T16:30:43.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 66afd7ad6fe085f612ae866be6517f9e897c4fba6e73e474a8e5d595bf17d99d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$3.41B
Price/FCF Ratio
19.54
TTM Avg
26.73
3Y Avg
53.68
5Y Avg
53.68
Market Cap
$3.51B
Price/FCF Ratio
N/A
TTM Avg
12.06
3Y Avg
12.04
5Y Avg
12.04
Market Cap
$3.53B
Price/FCF Ratio
90.67
TTM Avg
158.72
3Y Avg
191.31
5Y Avg
191.31
Market Cap
$3.12B
Price/FCF Ratio
N/A
TTM Avg
16.27
3Y Avg
21.05
5Y Avg
21.05
Market Cap
$3.56B
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Parabilis Medicines, Inc. (PBLS) | $3.35B | N/A | N/A | N/A | N/A |
| CareDx, Inc (CDNA)vs › | $3.39B | 39.81 | 30.07 | 190.37 | 190.37 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.40B | N/A | N/A | N/A | N/A |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.41B | 19.54 | 26.73 | 53.68 | 53.68 |
| Celcuity Inc. (CELC)vs › | $3.50B | N/A | N/A | N/A | N/A |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.51B | N/A | 12.06 | 12.04 | 12.04 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | 90.67 | 158.72 | 191.31 | 191.31 |
| Denali Therapeutics Inc. (DNLI)vs › | $3.12B | N/A | 16.27 | 21.05 | 21.05 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.56B | N/A | N/A | N/A | N/A |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.05B | 77.92 | 106.42 | 106.42 | 106.42 |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
